Accelerate Diagnostics Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Accelerate Diagnostics de winst en omzet met respectievelijk 0.4% en 1.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 13.3% per jaar.

Belangrijke informatie

0.4%

Groei van de winst

13.3%

Groei van de winst per aandeel

Medical Equipment winstgroei	15.8%
Inkomstengroei	1.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	30 Sep 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:1A80 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	13	-40	N/A	N/A	1
12/31/2024	12	-47	N/A	N/A	1
6/30/2024	12	-38	-33	-32	N/A
3/31/2024	12	-59	-37	-35	N/A
12/31/2023	12	-62	-41	-40	N/A
9/30/2023	12	-63	-43	-42	N/A
6/30/2023	12	-80	-48	-47	N/A
3/31/2023	13	-66	-50	-49	N/A
12/31/2022	13	-62	-49	-49	N/A
9/30/2022	13	-71	-52	-51	N/A
6/30/2022	13	-64	-51	-50	N/A
3/31/2022	12	-67	-48	-47	N/A
12/31/2021	12	-78	-48	-47	N/A
9/30/2021	12	-74	-46	-46	N/A
6/30/2021	12	-84	-47	-46	N/A
3/31/2021	11	-81	-47	-46	N/A
12/31/2020	11	-78	-52	-50	N/A
9/30/2020	12	-81	-55	-54	N/A
6/30/2020	10	-82	-60	-59	N/A
3/31/2020	10	-84	-64	-63	N/A
12/31/2019	9	-84	-65	-65	N/A
9/30/2019	8	-85	-66	-65	N/A
6/30/2019	7	-87	-66	-66	N/A
3/31/2019	7	-89	-71	-71	N/A
12/31/2018	6	-88	-69	-68	N/A
9/30/2018	6	-82	-68	-67	N/A
6/30/2018	5	-77	-65	-63	N/A
3/31/2018	4	-71	N/A	-56	N/A
12/31/2017	4	-64	N/A	-56	N/A
9/30/2017	2	-64	N/A	-55	N/A
6/30/2017	1	-64	N/A	-53	N/A
3/31/2017	1	-65	N/A	-56	N/A
12/31/2016	0	-66	N/A	-53	N/A
9/30/2016	0	-63	N/A	-50	N/A
6/30/2016	0	-57	N/A	-47	N/A
3/31/2016	0	-52	N/A	-41	N/A
12/31/2015	0	-45	N/A	-35	N/A
9/30/2015	0	-41	N/A	-30	N/A
6/30/2015	0	-39	N/A	-27	N/A
3/31/2015	0	-35	N/A	-22	N/A
12/31/2014	0	-31	N/A	-19	N/A
9/30/2014	0	-27	N/A	-17	N/A
6/30/2014	0	-22	N/A	-13	N/A
3/31/2014	0	-18	N/A	-11	N/A
12/31/2013	0	-15	N/A	-10	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 1A80 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 1A80 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 1A80 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 1A80 ( 1.8% per jaar) zal naar verwachting langzamer groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van 1A80 ( 1.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 1A80 naar verwachting over 3 jaar hoog zal zijn

Accelerate Diagnostics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System

Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial

Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021)

Insufficient new directors

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021)

Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022

Insider recently bought €80k worth of stock

Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2021)

Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.41 loss in 1Q 2021)

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven